LENZ
LENZ Therapeutics Inc.
$38.63
+$0.43(+1.13%)
50
Overall
60
Value
60
Tech
31
Quality
Market Cap
$1.10B
Volume
223.08K
52W Range
$16.54 - $41.70
Target Price
$49.71
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | -- | $15.0M | -- | -- | ||
| Total Revenue | -- | $15.0M | -- | -- | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $60.4M | $25.5M | $72.4M | $58.6M | ||
| Research & Development | $37.9M | $72.8M | $59.5M | $29.8M | ||
| Research Expense | $37.9M | $72.8M | $59.5M | $29.8M | ||
| Selling, General & Administrative | $22.5M | $32.9M | $12.9M | $28.8M | ||
| General & Administrative Expenses | $22.5M | $32.9M | $12.9M | $28.8M | ||
| Salaries & Wages | -- | -- | $1.3M | $6.4M | ||
| Depreciation & Amortization | $700.0K | $2.4M | $2.4M | -- | ||
| Depreciation & Amortization | $700.0K | $2.4M | $2.4M | -- | ||
| Other Operating Expenses | $-1.3M | $-1.9M | $-1.8M | $-2.3M | ||
| OPERATING INCOME | ||||||
| Operating income | $-60.4M | $-105.6M | $-72.4M | $-58.6M | ||
| EBITDA | $-70.0M | $-10.5M | $-70.1M | $-49.7M | ||
| NON-OPERATING ITEMS | ||||||
| Intinc | -- | -- | $2.2M | $8.6M | ||
| Net Non-Operating Interest Income/Expense | -- | -- | $2.2M | $8.6M | ||
| Gain on Sale of Securities | -- | $-1.0M | $1.0M | -- | ||
| Other Income/Expense | $10.3M | $19.0K | $-93.0K | $-289.0K | ||
| Other Special Charges | $-10.3M | $4.6M | $93.0K | $289.0K | ||
| SPECIAL ITEMS | ||||||
| Restructring And Mn A Income | -- | -- | $62.1M | -- | ||
| Special Income Charges | -- | -- | $-62.1M | -- | ||
| Other Impairment Of Capital Assets | -- | -- | $54.1M | -- | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-70.8M | $-10.5M | $-70.1M | $-49.8M | ||
| Pre-Tax Income | $-70.8M | $-10.5M | $-70.1M | $-49.8M | ||
| INCOME TAX | ||||||
| Tax Provision | -- | $347.0K | $-179.0K | $1.0K | ||
| NET INCOME | ||||||
| Net Income | $-70.8M | $-10.8M | $-70.0M | $-49.8M | ||
| Net Income (Continuing Operations) | $-70.8M | $-10.8M | $-70.0M | $-49.8M | ||
| Net Income (Discontinued Operations) | $-70.8M | $-10.8M | $-70.0M | $-49.8M | ||
| Net Income (Common Stockholders) | $-70.8M | $-10.8M | $-70.0M | $-49.8M | ||
| Normalized Income | $-55.9M | -- | -- | $-49.3M | ||
| TOTALS | ||||||
| Total Expenses | $60.4M | $25.5M | $72.4M | $58.6M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $4.1M | $7.8M | $8.1M | $21.3M | ||
| Average Shares Outstanding (Diluted) | -- | $7.8M | $8.1M | $21.3M | ||
| Shares Outstanding | $8.3M | $8.3M | $8.3M | $27.5M | ||
| Basic EPS | $-17.15 | $-12.88 | $-15.33 | $-2.34 | ||
| Basic EPS (Continuing Operations) | $-17.15 | $-12.88 | $-15.33 | $-2.34 | ||
| Diluted EPS | $-17.15 | $-12.88 | $-15.33 | $-2.34 | ||
| Diluted EPS (Continuing Operations) | -- | $-12.88 | $-15.33 | $-2.34 | ||
| OTHER METRICS | ||||||
| Gain On Sale Of P P E | -- | -- | $-71.0K | -- | ||
| Other Gand A | $22.5M | $32.9M | $12.9M | $28.8M | ||
| Restruct | -- | -- | $62.1M | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LENZ | $38.63 | +1.1% | 223.08K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |